Jan is ready for a new challenge. She's recently moved to Colorado and wants to take advantage of the new terrain and start mountain running. Before the move, she'd been working on her fitness for ...

The combination of PD-L1 and CTLA-4 inhibition improves disease-free survival after surgery in patients with primary renal cell carcinoma, a phase 3 trial finds. For patients with renal cell carcinoma ...

Less than half of the healthcare providers correctly identified refractory chronic cough (RCC) as a cough lasting more than 8 weeks and not responding to treatment, based on survey data from more than ...

Rockland's Senior Fair, hosted at SUNY Rockland Community College's fieldhouse, takes place Sept. 17. Rocklanders can get free flu shots, blood pressure checks, smoke alarms and more. The annual event ...

Git isn’t hard to learn. Moreover, with a Git GUI such as Atlassian’s Sourcetree, and a SaaS code repository such as Bitbucket, mastery of the industry’s most powerful version control tools is within ...

Lucas is a writer and narrative designer from Argentina with over 15 years of experience writing for games and news. He keeps a watchful eye at the gaming world and loves to write about the hottest ...

Moderate to advanced chronic kidney disease is an underappreciated burden of von Hippel-Lindau (VHL)-associated renal cell carcinoma (RCC) treated with surgery, which also includes frequent disease ...

Want to build the perfect starter house in Minecraft? 🏠 This easy step-by-step tutorial shows you how to create a compact, stylish, and resource-friendly house perfect for survival mode. Whether ...

Start your calisthenics journey with these nine foundational exercises, complete with easy-to-follow tutorials for each movement! #CalisthenicsForBeginners #BodyweightWorkout #FitnessTutorial 'Into ...

Casdatifan, an HIF-2α inhibitor, showed a 33% objective response rate in ccRCC patients at a 100 mg daily dose. The drug targets hypoxia-inducible factor-2 alpha to disrupt tumor-promoting mechanisms ...

A phase 2 study showed a 93.3% objective response rate for lenvatinib and tislelizumab in FH-RCC patients, with a 20% complete response rate. FH-RCC is driven by FH gene mutations, leading to early ...